A detailed history of Manufacturers Life Insurance Company, The transactions in Nkarta, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 10,735 shares of NKTX stock, worth $63,443. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,735
Holding current value
$63,443
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$5.59 - $15.71 $60,008 - $168,646
10,735 New
10,735 $116,000
Q2 2023

Aug 11, 2023

SELL
$2.19 - $5.17 $28,470 - $67,210
-13,000 Closed
0 $0
Q4 2022

Aug 11, 2023

BUY
$5.14 - $14.35 $904 - $2,525
176 Added 1.37%
13,000 $77,000
Q4 2022

Feb 13, 2023

BUY
$5.14 - $14.35 $904 - $2,525
176 Added 1.37%
13,000 $77,000
Q3 2022

Aug 11, 2023

SELL
$12.27 - $18.39 $4,331 - $6,491
-353 Reduced 2.68%
12,824 $168,000
Q3 2022

Nov 03, 2022

SELL
$12.27 - $18.39 $4,331 - $6,491
-353 Reduced 2.68%
12,824 $169,000
Q2 2022

Aug 11, 2023

BUY
$7.77 - $19.44 $1,375 - $3,440
177 Added 1.36%
13,177 $162,000
Q2 2022

Aug 15, 2022

BUY
$7.77 - $19.44 $102,385 - $256,160
13,177 New
13,177 $162,000
Q4 2021

Feb 16, 2022

SELL
$12.79 - $26.88 $99,467 - $209,045
-7,777 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$26.67 - $38.76 $16,162 - $23,488
-606 Reduced 7.23%
7,777 $216,000
Q2 2021

Aug 12, 2021

SELL
$23.94 - $36.68 $74,285 - $113,818
-3,103 Reduced 27.02%
8,383 $266,000
Q1 2021

May 03, 2021

BUY
$31.33 - $59.61 $51,443 - $97,879
1,642 Added 16.68%
11,486 $378,000
Q4 2020

Feb 12, 2021

BUY
$27.03 - $75.62 $27,246 - $76,224
1,008 Added 11.41%
9,844 $605,000
Q3 2020

Nov 09, 2020

BUY
$23.52 - $47.9 $207,822 - $423,244
8,836 New
8,836 $266,000

Others Institutions Holding NKTX

About Nkarta, Inc.


  • Ticker NKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,656,800
  • Market Cap $288M
  • Description
  • Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...
More about NKTX
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.